Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Schroder Investment Management Group

Schroder Investment Management Group reduced its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 5.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,125,618 shares of the company’s stock after selling 61,166 shares during the period. Schroder Investment Management Group owned 0.52% of Hims & Hers Health worth $28,332,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HIMS. Main Management ETF Advisors LLC acquired a new stake in shares of Hims & Hers Health during the 3rd quarter worth about $672,000. Means Investment CO. Inc. lifted its stake in shares of Hims & Hers Health by 23.5% during the fourth quarter. Means Investment CO. Inc. now owns 50,040 shares of the company’s stock valued at $1,210,000 after buying an additional 9,508 shares during the period. Principal Financial Group Inc. boosted its position in Hims & Hers Health by 102.0% during the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company’s stock worth $5,349,000 after acquiring an additional 146,621 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in Hims & Hers Health in the 4th quarter worth approximately $2,628,000. Finally, Pacer Advisors Inc. acquired a new position in Hims & Hers Health in the fourth quarter valued at $374,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Trading Up 0.4 %

NYSE:HIMS opened at $31.16 on Thursday. The firm has a market capitalization of $6.92 billion, a PE ratio of 70.82 and a beta of 1.37. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The stock has a 50 day moving average of $39.97 and a 200-day moving average of $29.79.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Citigroup reaffirmed a “sell” rating and set a $27.00 price target on shares of Hims & Hers Health in a research report on Thursday, March 6th. Morgan Stanley cut Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price objective for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Leerink Partners increased their target price on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday, February 25th. BTIG Research started coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Truist Financial upped their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $37.31.

Insider Transactions at Hims & Hers Health

In other news, COO Melissa Baird sold 67,687 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $29.35, for a total transaction of $1,986,613.45. Following the completion of the sale, the chief operating officer now directly owns 706,872 shares of the company’s stock, valued at $20,746,693.20. This trade represents a 8.74 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Andrew Dudum sold 36,460 shares of the business’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $27.09, for a total value of $987,701.40. Following the sale, the chief executive officer now directly owns 27,918 shares in the company, valued at $756,298.62. This trade represents a 56.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,064,954 shares of company stock valued at $37,984,259 in the last quarter. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.